211
Participants
Start Date
February 2, 2015
Primary Completion Date
October 7, 2015
Study Completion Date
October 7, 2015
Benralizumab
Benralizumab administered subcutaneously every 4 weeks
Placebo
Placebo administered subcutaneously every 4 weeks
Research Site, Százhalombatta
Research Site, Balassagyarmat
Research Site, Komárom
Research Site, Miskolc
Research Site, Pécs
Research Site, Pécs
Research Site, Berlin
Research Site, Winston-Salem
Research Site, Raleigh
Research Site, Monroe
Research Site, Charlotte
Research Site, Spartanburg
Research Site, Hanover
Research Site, Orlando
Research Site, Clearwater
Research Site, Grove City
Research Site, Cincinnati
Research Site, Frankfurt am Main
Research Site, Blue Island
Research Site, Frankfurt
Research Site, Neu-Isenburg
Research Site, Oklahoma City
Research Site, San Antonio
Research Site, El Paso
Research Site, Los Angeles
Research Site, Rolling Hills Estates
Research Site, Bamberg
Research Site, Medford
Research Site, Skillman
Research Site, Vancouver
Research Site, Ajax
Research Site, Burlington
Research Site, Hamilton
Research Site, Ottawa
Research Site, Toronto
Research Site, Québec
Research Site, Québec
Research Site, Saint-Charles-Borromée
Research Site, Trois-Rivières
Research Site, Katowice
Research Site, Mrągowo
Research Site, Ostrów Wielkopolski
Research Site, Pabianice
Research Site, Poznan
Research Site, Poznan
Research Site, Tarnów
Research Site, Wroclaw
Research Site, Wroclaw
Research Site, Bratislava
Research Site, Bratislava
Research Site, Humenné
Research Site, Košice
Research Site, Levice
Research Site, Poprad
Research Site, Prešov
Research Site, Vráble
Research Site, Žilina
Lead Sponsor
AstraZeneca
INDUSTRY